Inquiry Basket
Loading ......
Alemtuzumab is a humanized immunoglobulin gamma one kappa (IgG1κ) monoclonal antibody that targets CD52, a glycoprotein expressed at high levels on the surface of mature lymphocytes including B cells, T cells, natural killer cells, monocytes, and macrophages. By binding to CD52, Alemtuzumab triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to rapid and prolonged depletion of circulating lymphocytes. This profound immunosuppressive effect underlies both the therapeutic efficacy and the unique safety profile of Alemtuzumab in clinical use.The immunogenicity of Alemtuzumab has been a subject of extensive investigation due to its impact on treatment outcomes. Anti-Alemtuzumab antibodies can develop following treatment and may influence drug pharmacokinetics, reduce therapeutic efficacy, and contribute to adverse events. Accurate detection and characterization of anti-Alemtuzumab antibodies are therefore essential for understanding the clinical pharmacology of this therapeutic antibody and for optimizing patient management strategies.
Figure 1.Anti-Alemtuzumab Antibody ELISA Kits.
CD52 is a glycosylphosphatidylinositol-anchored glycoprotein expressed abundantly on the surface of mature lymphocytes. The biological function of CD52 is not fully understood, but its high expression on lymphocytes and relative absence on other cell types makes it an attractive target for therapeutic intervention. The density of CD52 on lymphocyte surfaces is exceptionally high, with each cell bearing hundreds of thousands of CD52 molecules. Upon binding to CD52 on lymphocyte surfaces, Alemtuzumab engages immune effector mechanisms that result in target cell destruction. The Fc region of Alemtuzumab interacts with Fc gamma receptors on effector cells such as natural killer cells and macrophages, triggering antibody-dependent cellular cytotoxicity. Additionally, Alemtuzumab activates the complement cascade, leading to formation of membrane attack complexes and complement-dependent cytotoxicity. The combination of these effector mechanisms produces rapid and profound lymphocyte depletion following Alemtuzumab administration.
Relapsing-remitting multiple sclerosis is characterized by episodes of neurological dysfunction caused by inflammatory demyelination in the central nervous system. Autoreactive lymphocytes that recognize myelin antigens are central to disease pathogenesis. By depleting circulating lymphocytes, Alemtuzumab removes the cellular mediators of this autoimmune response. Clinical trials have demonstrated that Alemtuzumab reduces annualized relapse rates, delays disability progression, and reduces magnetic resonance imaging lesion activity in patients with relapsing-remitting multiple sclerosis. The dosing regimen typically involves two annual courses of intravenous administration. Lymphocyte depletion following treatment is profound and prolonged, with recovery occurring over many months to years. A unique feature of Alemtuzumab in multiple sclerosis is the occurrence of secondary autoimmune disorders in a subset of treated patients. These autoimmune events, which include immune thrombocytopenia, thyroid disorders, and nephropathies, are thought to result from reconstitution of the immune system following lymphocyte depletion. Close monitoring of patients is therefore essential.
B-cell chronic lymphocytic leukemia is characterized by accumulation of malignant CD52-positive B cells in the blood, bone marrow, and lymphoid tissues. Alemtuzumab targets these malignant cells, inducing their destruction through the same immune effector mechanisms active in multiple sclerosis. Alemtuzumab is indicated for the treatment of B-cell chronic lymphocytic leukemia in patients who have failed other therapies. The efficacy of Alemtuzumab is particularly notable in patients with certain high-risk genetic features. However, the profound immunosuppression induced by Alemtuzumab increases susceptibility to opportunistic infections, necessitating prophylactic antimicrobial therapy and careful monitoring.
Treatment with Alemtuzumab is associated with development of anti-drug antibodies in a subset of patients. The incidence of anti-Alemtuzumab antibodies varies depending on the assay methodology, sampling timing, and patient population studied. Anti-Alemtuzumab antibodies may be neutralizing or non-neutralizing, with neutralizing antibodies possessing the ability to block the binding of Alemtuzumab to CD52 and thereby inhibit its biological activity. The timing of anti-drug antibody development following Alemtuzumab administration is influenced by the profound lymphocyte depletion induced by the drug. Because antibody-producing B cells are eliminated by Alemtuzumab, anti-drug antibody responses may be delayed until B-cell reconstitution occurs. This unusual pharmacokinetic-immunogenicity relationship complicates interpretation of anti-drug antibody data.
Anti-Alemtuzumab antibodies can have clinically significant consequences. Neutralizing antibodies may reduce the efficacy of subsequent Alemtuzumab doses by blocking drug binding to CD52. Non-neutralizing antibodies may alter drug pharmacokinetics by accelerating clearance, leading to reduced drug exposure. Additionally, anti-drug antibodies may contribute to infusion-related reactions and other adverse events. The relationship between anti-Alemtuzumab antibodies and secondary autoimmune events in multiple sclerosis has been investigated. While no direct causal link has been established, the timing of anti-drug antibody development relative to immune reconstitution and autoimmune events suggests complex interactions that warrant continued study.
The Anti-Alemtuzumab Antibody ELISA Kit is designed for the detection and semi-quantitative determination of anti-Alemtuzumab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
Alemtuzumab is an important therapeutic antibody for the treatment of relapsing-remitting multiple sclerosis and B-cell chronic lymphocytic leukemia. Its mechanism of action involves targeting CD52 on lymphocytes, leading to profound and prolonged lymphocyte depletion. Immunogenicity assessment is essential for understanding the clinical pharmacology of Alemtuzumab, as anti-drug antibodies can influence drug pharmacokinetics, therapeutic efficacy, and patient safety. The Anti-Alemtuzumab Antibody ELISA Kit provides a validated, sensitive, and specific solution for detecting anti-Alemtuzumab antibodies in human biological samples. The kit supports screening and confirmatory testing strategies, enabling comprehensive immunogenicity profiling that meets regulatory expectations. Key performance characteristics including high sensitivity, excellent specificity, and excellent reproducibility ensure reliable results that support clinical development and post-marketing surveillance. As the use of Alemtuzumab continues to expand, reliable anti-drug antibody detection will remain essential for optimizing patient management and understanding the immunogenicity of this unique therapeutic antibody.
| Cat. No. | Product Name | Species Reactivity | Application | |
| DEIA-JY25234 | Anti-Alemtuzumab ELISA Kit | Human | This kit is designed for the quantitative detection of Anti-Alemtuzumab in serum and plasma using ELISA methodology. For research use only (RUO). Not for diagnostic procedures. | Inquiry |
Loading ......
